alexa The FIRM Trial A Large Double-blind Randomized Controlled Trial Of Ferumoxytol Vs. Ferric Carboxymaltose For The Treatment Of Iron Deficiency Anemia | 71091
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

International Conference on Hematology and Oncology

William Strauss
AMAG Pharmaceuticals, USA
Posters & Accepted Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864-C1-026
Abstract
Over the past 2 decades IV iron preparations have found widespread usage in multiple disease states resulting in IDA which has been inadequately treated with oral irons. Yet, there is a remarkable paucity of large controlled studies comparing these agents head to head , especially of sufficient size to assess the incidence of rare adverse events such as hypersensitivity reactions and major hypotension. The 2 most recently approved IV iron agents in the US, ferumoxtytol (Fer) and ferric carboxymaltose (FCM) are able to deliver a full course of iron administered in 2 doses. The FIRM study (IDA-304) is a multicenter study conducted in ~180 sites in North America and Europe. Just over 2,000 patients with a diagnosis of IDA of any etiology, who are intolerant to oral iron, received either 2x510mg of Fer, or 2x750mg of FCM in a double blind fashion. Efficacy is assessed by mean change in hemoglobin and change in hemoglobin/mg of iron over the 5 week study. Safety focuses on the occurrence of moderate or severe hypersensitivity reactions (HSRs), including anaphylaxis, and moderate to severe hypotension. All potential HSRs are adjudicated by a blinded Clinical Events Committee. 2015 patients have been randomized, with the final patient visit in January 2017. Results will be available during 2Q17 and presented.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version